Five Questions with JLL Partners’ Daniel Agroskin

JLL Partners, Daniel Agroskin, private equity, merger, M&A
  • JLL closed its seventh fund at $1 bln in April 2016
  • New York sponsor looks to invest early in underlooked themes
  • Recent exits in pharma services: Patheon, BioClinica
Daniel Agroskin is a managing director at JLL Partners, where he leads the New York private equity firm’s healthcare efforts and is a member of the management committee. How would you describe JLL’s broader approach to healthcare investing? The way ...

This content is available for Buyouts subscribers only. Request a free trial to get access for a limited period

If you already have an active Buyouts subscription, please sign in to view this article.

Digital Edition


To read a digital copy of our latest magazine

click here

PE News Briefs